Table 2.

Aberrations of MYCN in human disorders.

Disease	Onset	Primary Location	MYCN Aberration	% of Patients Showing MYCN Aberration
Neuroblastoma	Childhood	Peripheral nervous system	Amplification/overexpression	25%
Medulloblastoma	Childhood	Cerebellum	Amplification	7–10%
Retinoblastoma	Childhood	Retina	Amplification	2%
Rabdomyosarcoma (ARMS/ERMS)	Childhood	Skeletal muscle	Copy number gain/amplification/Increased stability	25% of ARMS 16% of ERMS
Wilms’ tumor	Childhood	Kidney	Copy number gain/Overexpression/mutation	13% 9% 4%
Feingold syndrome	Childhood	Physical and learning developmental disorders	Amplification/ deletion/loss of function	50%
Leukemia (CLL/ALL)	Childhood/adulthood	White blood cells	Copy number gain/amplification/Increased expression	7% of ALL 35% of CLL
Prostate cancer	Adulthood	Prostate	Amplification	14%
Basal cell carcinoma	Adulthood	Skin	Copy number gain/increased expression	18% 73%
Lung cancer	Adulthood	Lung	Copy number gain	6%

ARMS: Alveolar rhabdomyosarcoma; ERMS: Embryonal rhabdomyosarcoma; CLL: Chronic lymphocytic leukemia; ALL: Acute lymphoblastic leukemia.